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Abstract: Venoms are produced by a wide variety of species including spiders, scorpions, reptiles,
cnidarians, and fish for the purpose of harming or incapacitating predators or prey. While some
venoms are of relatively simple composition, many contain hundreds to thousands of individual
components with distinct pharmacological activity. Pain-inducing or “algesic” venom compounds
have proven invaluable to our understanding of how physiological nociceptive neural networks
operate. In this review, we present an overview of some of the diverse nociceptive pathways that can
be modulated by specific venom components to evoke pain.
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1. Venoms and Their Pharmacological Effects
Venoms can be defined broadly as toxins secreted by an animal for the purpose of harming or
incapacitating predators or prey. Venoms are widely used by spiders, scorpions, reptiles, cnidarians,
fish, and by a few mammals and marsupials. While some venoms are of relatively simple composition,
many contain hundreds to thousands of individual components with distinct pharmacological
activity [1–4]. Given the substantial metabolic production cost to venomous animals, it is therefore
likely that these venom components confer some survival benefit, although it should be noted that this
remains unclear for the vast majority of venom components.
Most commonly, venoms are delivered to the victim through wounds resulting from encounters
with physical defence mechanisms such as claws, teeth, quills, spines and stingers. However, topical
delivery of venoms, for example, to the eye has also evolved, in the case of spitting cobras, multiple
times [5]. Broadly, venoms can be categorised as cytotoxic or neurotoxic; either mechanism can induce
pain on envenomation, although many venoms are either non-noxious or even analgesic [5]. The latter
include venoms that block voltage-gated calcium channels or voltage-gated sodium channels, either
directly or indirectly via G-protein coupled receptors [1,6–8]. Paralytic toxins are often hypothesised
to have evolved specifically for predatory purposes, while pain-inducing venoms are intuitively well
suited for defensive purposes. Indeed, some of the most painful venoms—such as bee, wasp, stonefish
or platypus venom—are only used for defensive or competitive purposes. However, paralytic effects
and nociceptive activity are not mutually exclusive, suggesting that pain-inducing venom components
may serve a dual purpose and that this simplistic classification is likely to be revised following
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advances in venom research. In addition, venomous animals are surprisingly adept at modulating the
composition and amount of venom produced.
For example, cone snails such as Conus geographus are able to switch—rapidly, repeatedly and
interchangeably—between venom containing high levels of paralytic toxins when faced with a human
or predator, or venom containing prey-specific toxins that are mostly inactive at human targets when
hunting for a meal [9]. Similarly, the spider Cupiennius salei, as well as several snakes, are able to adjust
the amount of injected venom based on prey size [10,11]. Thus, the correlation of toxin abundance
in dissected or extracted venom with pain reported after envenomation is likely confounded by
erroneous assumptions about the evolutionary purpose of individual venom components with specific
pharmacological activity.
Overall, algesic and analgesic venom compounds have proved invaluable to our understanding
of how our physiological nociceptive neural networks operate. In this review, we present an overview
of the nociceptive channels and neuronal pathways that are commonly modulated by specific venom
components. Specifically, we highlight those venoms that induce nociceptive responses, and the
diversity of mechanisms that these venoms target to evoke nociception.
2. The Neurobiology of Peripheral Pain Detection and Processing
Pain is indisputably a powerful motivator, and a crucial mechanism necessary for survival,
as it allows an organism to alter its normal behaviours to protect the site of injury and facilitate
proper tissue healing. Pain also encourages learnt avoidance behaviours that serve to prevent future
exposure to noxious stimuli [12]. The evolutionary benefit of pain is convincingly illustrated by
congenital insensitivity and indifference to pain, conditions arising from multiple genetic mutations
that are associated with dysfunction of the nociceptive system. The resultant complete absence of pain
sensations can lead to risk-seeking and self-mutilating behaviours that often lead to premature death
as a result of trauma [13,14]. These incidents graphically illustrate the utility of pain for the defence
of an organism against potentially life-threatening stimuli. Accordingly, activation of an organism’s
nociceptive signalling system by venom peptides is a highly effective envenomation strategy.
At the anatomical level, pain is typically the result of activation of nociceptive or “pain-sensing”
peripheral nerve endings, which primarily consist of thinly myelinated Aδ and sparsely or
unmyelinated C-fibre neurons [15]. The cell bodies of these neurons are located in the dorsal root
ganglia, with the central branches of the axons terminating in the spinal cord, where they form
synapses with second order neurons in the dorsal horn [15]. Signals originating from peripheral
nociceptors further ascend via the spinothalamic as well as spinoreticular, spinomesencephalic and
spinohypothalamic tracts for processing of pain perception in multiple higher brain centres [15].
Activation of nociceptors involves transduction of an external signal into a graded depolarisation of
the nerve terminal. This typically occurs via a myriad of receptors and ion channels that respond to
a range of chemical, mechanical, or thermal stimuli. For example, in recent years the Acid Sensing
Ion Channels (ASICs) have emerged as key contributors to acid detection, whilst the Transient
Receptor Potential (TRP) family of ion channels have been identified as key thermosensors encoding
a broad range of temperatures from very cold to burning hot. Generator potentials—small, graded
depolarisation—induced by activation of these ion channels in turn leads to the generation of action
potentials, which transmit peripheral events along the axon of sensory neurons (Figure 1).
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Figure 1. Pain due to envenomation typically occurs as a result of activation of nociceptive or
“pain-sensing” peripheral nerve endings which express a host of ion channels and receptors that
are targeted by venom components. Key molecular targets of algesic venom components include
ASICs, TRPV1, TRPA1, NaV and KV channels. Activation of ASICs and TRPs contribute to generator
potentials—small, graded depolarisation. KV channels play key roles in setting the resting membrane
potential, whilst once a threshold of membrane depolarisation has been reached, the opening of NaV
channels leads to the rapid upstroke of the action potential.
The threshold of action potential generation, or transformation of a nociceptive signal, is regulated
tightly by ion channels involved in setting the resting membrane potential. Of particular importance
in this regard are the potassium channels, in particular members of the voltage-gated (KV), two-pore
domain (K2P) and inward rectifier (Kir) families (voltage-gated and K2Ps), as well as the Na+/K+-ATPase
which maintains the required ionic gradients. To a lesser degree, hyperpolarisation-activated cyclic
nucleotide-gated, voltage-gated Na+ channels (NaV), and voltage-gated Ca2+ channels (CaV) also
contribute to setting the resting membrane potential [16]. Once a threshold of membrane depolarisation
has been reached, the opening of NaV channels leads to the rapid upstroke of the action potential.
The biophysical processes of signal transduction, transformation and transmission offer a
multitude of opportunities for venomous animals to elicit pain. In addition to the physical injury
associated with a bite or sting (which may be minor), activation of Na+- or Ca2+-permeable channels
or signalling pathways that lead to the downstream intracellular elevation of these ions results in
membrane depolarisation and transformation of these generator potentials into action potentials.
Alternatively, inhibition of ion channels that contribute to setting and/or maintaining the resting
membrane potential can also achieve net excitatory effects, and thus induce pain. Often, venom
components have dual activity and both activate Na+- or Ca2+-permeable channels and inhibit
K+-permeable channels, causing synergistic activation of nociceptors, although it should be noted
that for the vast majority of venom components, direct effects on sensory neurons and pain
behaviours have not been assessed. This envenomation strategy effectively “hi-jacks” the body’s
normal nociceptive pathways. In addition to specific modulation of molecular targets, a “molecular
sledgehammer” approach to inducing pain is via pore-forming toxins, which allow indiscriminate ion
flux. Specific toxins that act via some of these pathways are discussed in the following sections.
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3. Voltage-Gated Sodium Channels
Voltage-gated sodium (NaV) channels are key transmembrane proteins that contribute to setting
the resting membrane potential, and that are essential for propagation of action potentials in nociceptive
neurons [17,18]. Nine subtypes, called NaV1.1–NaV1.9, have been identified and are encoded by the
genes SCN1A-SCN5A and SCN8A-SCN11A [18]. Gain of function mutations that result either in
enhanced activation or delayed inactivation have been associated with various conditions linked to
enhanced pain, including paroxysmal extreme pain disorder and inherited erythromelalgia [7,19,20].
Although it is not a venom, the pan-NaV channel activator ciguatoxin (P-CTX-1) is of interest
as it causes ciguatera, the most common non-bacterial form of fish-borne illness in humans due to
the consumption of fish contaminated with ciguatoxins [21,22] Key symptoms of ciguatera include
heightened nociception, cold-allodynia and abdominal pain. Accordingly, ciguatoxin provides a key
tool for comparison to venom based NaV activators described below. Studies show that simultaneous
activation of all NaV channels by P-CTX-1 produces nocifensive responses when administered
subcutaneously or intra-colonically in mice [21]. In mice, the somatosensory responses are likely
mediated via NaV1.6 and NaV1.7 activation, as shown by inhibitory pharmacological modulation.
In contrast, P-CTX-1 induced visceral pain appears to be predominantly mediated via NaV1.8 [21],
highlighting the differing role of NaV channels between somatic and visceral innervating nociceptors.
In conjunction with these findings, researchers have discovered compounds in painful scorpion
venoms that selectively activate NaV1.6 (Cn2) and NaV1.7 (OD1) [23–26]. Intraplantar injections of
either purified venom peptide activates spontaneous pain behaviour, and, interestingly, activation of
different pain modalities [23–26].
As NaV channels are highly conserved across many phyla, the spastic paralysis induced by
envenomation with NaV activators has likely contributed to the evolutionary success of these
compounds, resulting in convergent recruitment of this pharmacology.
Perhaps as a fortuitous coincidence—from the venomous animals’ perspectives—NaV activators
also typically elicit nocifensive responses after local injection. While subtype-selectivity for
mammalian NaV isoforms is likely not required as activation of at least NaV1.1, NaV1.6, NaV1.7
and NaV1.8 results in pain, structural similarities of mammalian NaV isoforms to prey channels
(e.g., fish and insect) in conjunction with differences between mammalian isoforms has led to
the evolution of highly subtype-selective NaV probes. Accordingly, NaV channel activator toxins
have been found in many venomous animals, including cone snails (δ-conotoxin SuVIA from
Conus suturatus), spiders (e.g., δ-theraphotoxin-Hm1a from Heteroscodra maculata), sea anemone
(e.g., ATX-II from Anemonia sulcata), scorpions (e.g., α-scorpion toxin CvIV4 from Centruroides
vittatus), wasps (e.g., α-pompilidotoxin from Anoplius samariensis), and snakes (δ-elapitoxin-Cb1a
from Calliophis bivirgata) (see Table 1) [27–31]. Generally speaking, such toxins achieve functional
activation of NaV channels through hyperpolarising shifts in the voltage-dependence of channel
activation, depolarising shifts in channel inactivation, and through delaying the time-course of
inactivation [21,32,33]. The net effect of these actions is typically enhanced neuronal excitability
and activation of nociceptive pathways.
The recent discovery of δ-theraphotoxin-Hm1a (Hma1), a selective NaV1.1 modulator that
impairs channel inactivation, revealed an unexpected role for NaV1.1 in mechanical pain [27].
Hm1a injection into the hind paw resulted in immediate nocifensive behaviours [27]. The genetic or
pharmacologic elimination of TRPV1-expressing fibres greatly decreased sensitivity to heat, but did
not affect sensitivity to mechanical stimuli, suggesting that NaV1.1 could potentially play a role in the
transmission and transduction of mechanical stimuli [27]. Indeed, genetic deletion of NaV1.1 led to a
decrease in nocifensive responses and decreased mechanical sensitisation [27].
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Table 1. Examples of pain-inducing venom peptides with activity at voltage-gated sodium channels
(NaV).
Venom Peptide Species Pharmacological Target(s) Pain Phenotype (Route) Reference
δ-theraphotoxin-Hm1a Heteroscodra maculata NaV1.1
Spontaneous pain (i.pl.),
mechanical allodynia (i.pl.) [27]
OD1 Odontobuthus doriae NaV1.7 Spontaneous pain (i.pl.) [25]
Cn2 Centruroides noxius NaV1.6
Spontaneous pain (i.pl.),
mechanical allodynia (i.pl.) [23]
δ-conotoxin SuVIA Conus suturatus NaV1.3, NaV1.4, NaV1.6, NaV1.7 Spontaneous pain (i.pl.) [31]
α-scorpion toxin CvIV4 Centruroides vittatus NaV1.2, NaV1.3, NaV1.4, NaV1.7 Spontaneous pain (i.pl.) [24]
Mechanical allodynia and hyperalgesia to colonic distension are crucial contributors to
abdominal pain in patients with irritable bowel syndrome (IBS) [34,35]. Application of Hm1a
enhanced mechanically-evoked firing in a sub-population of high-threshold colonic nociceptors in
mice [27]. This effect was blocked by incubation with the NaV1.1/NaV1.3 antagonist ICA-121431 [27].
Furthermore, Hm1a also induces hyper-excitability of isolated colon-innervating DRG neurons from
healthy control mice [27]. Importantly, colon-innervating DRG neurons isolated from a mouse model
of IBS showed significantly enhanced responsiveness to Hm1a compared to healthy control mice,
suggesting that NaV1.1 may be essential for the development and maintenance of chronic visceral pain
conditions [27]. As such, antagonism of NaV1.1 may be a future target for the treatment of disorders
accompanied by chronic visceral pain originating from the colon.
While systematic studies into the co-evolution of the pain system and pain-causing toxins are
largely lacking, this evolutionary arms race is poignantly illustrated by the evolution and function
of ion channels in specific species that frequent the habitat of venomous animals. For example,
Grasshopper mice are resistant to the painful venom of bark scorpion which they prey on, due to
a mutation in NaV1.8 [36]. Recently, pallid bats were also shown to be resistant to bark scorpion
venom [37], providing key insight into binding sites, gating, and evolution of the channel.
Venom compounds that modulate NaV channels have been extensively investigated for their
potential to treat several forms of pain, and, although NaV antagonists are outside the scope of this
review, several excellent reviews of venom-derived NaV antagonists are available (see [38]).
4. Transient Receptor Potential Channels
The transient receptor potential (TRP) channels belong to a superfamily of cation channels with
diverse tissue distribution in multicellular organisms [39], and in humans includes 27 members
in six subfamilies: TRPA(1), TRPV(1-6), TRPM(1-8), TRPP(1-3), TRPC(1,3-6), and TRPML(1-3) [40].
While TRP channels are expressed in almost every cell type in the body and have very diverse functions,
they participate in nociceptive signalling primarily by relaying information on noxious temperature,
chemicals, and pressure. Temperature detection is a particularly prominent role of TRPs, and it is
generally thought that TRPV1-4 and TRPM2-5 channels respond to warm or hot temperatures, and that
TRPA1, TRPM8, and TRPC5 respond to cool or cold temperatures, with preference for noxious or
physiological temperature stimuli for each subtype within each category [40–50].
4.1. TRPV1
TRPV1 is activated by capsaicin, the active ingredient in hot chilli peppers, by noxious chemicals,
and moderate heat under normal conditions. Interestingly, during in vitro pH conditions similar
to that of algesic tissue acidosis, there is a shift in the activation threshold of TRPV1 to room
temperature [39,51,52]. As a consequence of TRPV1 activation, there is a large influx of Ca2+,
Na+, Mg2+ or Zn2+ ions, resulting in action potential generation in several classes of nociceptors.
This mechanism is exploited by several venom-derived peptides acting at TRPV1, including RhTx
from the Chinese red-headed centipede (Scolopendra subspinipes mutilans) [53], BmP01 from the
scorpion Mesobuthus martensii [54], the selective and irreversible DkTx from the Earth Tiger tarantula
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Ornithoctonus huwena [55], venom components from the Palestine saw-scaled viper Echis coloratus [56],
as well as vanillotoxins including VaTx3 from the tarantula Psalmopoeus cambridgei [57] (Table 2).
Table 2. Examples of venom peptide activators of TRPV1.
Venom Peptide Species Pharmacological Target(s) Reference
RhTx Scolopendra subspinipes mutilans TRPV1 [53]
BmP01 Mesobuthus martensii TRPV1 [54]
DkTx Ornithoctonus huwena TRPV1 [55]
Echis coloratus venom Echis coloratus TRPV1 [56]
VaTx1 (τ/κ-theraphotoxin-Pc1a) Psalmopoeus cambridgei TRPV1, KV2.1 [57]
VaTx2 (τ-theraphotoxin-Pc1b) Psalmopoeus cambridgei TRPV1, KV2.1 [57]
VaTx3 (τ-theraphotoxin-Pc1c) Psalmopoeus cambridgei TRPV1 [57]
Interestingly, TRPV1 has relatively high structural similarity to the Shaker family of KV
channels, all of which are thought to form homo-or heteromultimeric proteins consisting of four
six-transmembrane domain subunits. Several venom compounds that act as TRPV1 agonists have
dual activity at voltage-gated potassium (KV) channels, perhaps suggesting that activity at TRPV1
is a natural extension of the pharmacology of venom peptides. Indeed, the vanillotoxins are
closely related to K+ channel inhibitor toxins and both VaTx1 (τ/κ-theraphotoxin-Pc1a) and VaTx2
(τ-theraphotoxin-Pc1b) are known inhibitors of KV2.1 channels; this dual activity may contribute to
pain-inducing effects in vivo [55].
While VaTx3 (τ-theraphotoxin-Pc1c) appears selective for TRPV1 over KV2.1, and no inhibition
at KV1.2 was observed for any of the vanillotoxins, activity at other K+ channel isoforms cannot be
ruled out at present [57]. Nonetheless, intraplantar administration of VaTx3 at >EC90 concentration
(20 µM) caused TRPV1-mediated paw licking behaviours that were entirely abolished in TRPV1−/−
animals [57]. Interestingly, VaTx1 binds to distinct, non-homologous regions of the KV and TRPV1
channels, suggesting that activity at TRPV1 is not simply a case of molecular and evolutionary
pharmacology promiscuity [55]. Recently, it has been shown that the TRPV1-agonist scorpion venom
peptides BmP01, Tx203, and OdK1 of the α-KTX8 scorpion peptide family all significantly potentiate
TRPV1 under acidic conditions both in vitro and in vivo [58].
Venom peptides have also been crucial in the determination of the structure of TRPV1 and
its distinct conformations in activate states [59–61]. Mutagenesis studies demonstrated that of the
two putative extracellular protonation sites of TRPV1, BmP01 interacts with the outer pore and
simultaneously occupies one of the protonation sites at E649. Mutation of the second protonation
site E601 to alanine removed the enhanced activity of BmP01 during acidic conditions. More recently,
DkTx was used to trap TRPV1 in an open configuration, enabling elucidation of the mechanisms of
TRPV1 activation [62].
4.2. TRPA1
TRPA1 initiates pain signalling due to inflammatory mediators and noxious cold, and has a
well-established role in toxin-induced pain [22]. Interestingly, no algesic venom peptide activator
of TRPA1 has been described, although several peptides elicit analgesic effects via inhibition or
activation-induced desensitisation of this channel [63–66].
The spider peptide ProTx-I (Thrixopelma pruriens) is analgesic in certain conditions, and a potent
antagonist of several Nav isoforms and TRPA1, possibly through interaction with the extracellular
loops of the S1–S4 gating domain of both channel families [63]. Similarly, Phα1β (Phoneutria nigriventer)
is a CaV and TRPA1 antagonist, and has been shown to attenuate mechanical and cold hyperalgesia
induced by the TRPA1 agonist allyl isothiocyanate (AITC) in vivo [65]. On the other hand, the sea
anemone venom peptide Ms 9a-1 is a positive modulator for TRPA1 in vitro and produces analgesic
and anti-inflammatory responses in vivo, possibly via a desensitisation mechanism [66]. Similarly,
crotalphine, a small venom peptide from a South American rattlesnake (Crotalus durissus terrificus), is a
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partial activator of TRPA1 and causes strong desensitisation of the channel, which may be responsible
for its analgesic effect in vivo [64,67]. Taken together, these findings suggest that while TRPA1 is
crucial for inflammatory and noxious cold signalling, it is not typically a key target of venom-induced
pain. It is plausible that the paucity of venom peptide TRPA1 activators described to date arises from
the unique signalling mechanism of TRPA1, which is robustly activated by reactive chemicals via
modification of cysteine residues. Similarly, only indirect activation mechanisms have been reported
for other TRP channel family members. For example, melittin-induced pain responses were reversed by
the non-selective TRPC inhibitor SKF-96365, although neither direct channel activation nor off-target
effects were assessed [68]. Given the important roles of TRP channels in sensory neuropharmacology,
as well as the diversity of chemical and physical TRP channel activators, it is likely that further TRP
modulators will be discovered from venoms in the future.
5. Voltage-Gated Potassium Channels
In the human genome, forty known genes encode the α subunits of voltage-gated potassium
channels (KV) [69]. Similar to NaV channels, KV channels consist of four pore-forming α-subunits
containing six transmembrane segments (S1–S6) that form a functional tetramer [70,71]. As some
subfamilies of potassium channels (namely, KV1 or KV7) can form heteromultimers with other
α-subunits, this results in considerable channel diversity with differing pharmacological and
biophysical characteristics [72]. Sensory neurons express several KV isoforms that repolarise the
membrane potential following an action potential and are pathologically involved in hyperexcitability
following injury and neuropathy [73–75].
The intrinsic function of KV channels is to oppose membrane depolarisation or action potential
generation and subsequent propagation [74]. Thus, KV channels have an inhibitory role in sensory
neuron excitability [74]. Decreased KV activity is a hallmark of the hyper-excitability demonstrated in
traumatic injuries and neuropathy [74].
Like NaV toxins, venom peptides can block KV function through occlusion of the pore, or by
binding to the voltage-sensing domains to alter channel function [76]. KV inhibitors have been isolated
from the venom of many species, including cone snails (e.g., κM-conotoxin RIIIK from Conus radiatus),
scorpions (e.g., Ts8 from Tityus serrulatus), spiders (e.g., κ-theraphotoxin-Gr1a from Grammostola
spatulata), snakes (e.g., α-dendrotoxin from Dendroaspis angusticeps) and sea anemone (e.g., BDS-II from
Anemonia sulcata [77–80].
Surprisingly, despite a clear role for KV channels in regulating sensory neuron excitability (for review
see [73]), the pain-inducing effects of KV inhibitors have not been assessed systematically, albeit some KV
inhibitors have well-described effects on sensory neuron function. As an in-depth discussion of the role of
potassium channels in pain pathways is beyond the scope of this review, the reader is referred to several
excellent publications on the matter [73,75,81,82]. In brief, sensory neurons express many KV isoforms,
including KV 1.1, 1.2, 1.3, 1.4, 1.6, 2.1, 2.2., 3.1, 3.2, 3.3, 3.4, 4.1, 4.3, 6.2, 6.4, 11.1, 10.2, 11.2, 11.3, 12.1, 7.1–7.5,
9.1, 9.3, and KV8.1 [83]. While the precise contribution(s) of these isoform to sensory signalling remain
unclear, toxins with activity at these channels could be expected to lead to enhanced nociception. Indeed,
dendrotoxin was shown to induce cold allodynia via KV1-mediated regulation of cold-sensitive trigeminal
neurons in concert with TRPM8 [84]. Similarly, Ts8—a scorpion venom toxin that selectively inhibits
KV4.2 over KV1.1–1.6, 2.1, 3.1, 7.1, 7.2, 7.4, 7.5, and KV10.1—elicited spontaneous nociceptive behaviour
after intraplantar injection as well as mechanical allodynia after intrathecal injection [78]. In addition to
providing an excellent defensive strategy, KV channel inhibitor toxins will undoubtedly provide important
research tools to unravel the complex pharmacology of these important ion channels.
6. Acid-Sensing Ion Channels
The Acid-sensing ion channel (ASIC) family contains six subunits (ASIC1a, ASIC1b, ASIC2a,
ASIC2b, ASIC3 and ASIC4) encoded by four genes (ASIC1–4) [85,86]. ASIC1, -2, and -3 are highly
expressed in the peripheral nervous system (PNS), where they are involved in detecting localised acidic
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pH changes and mediate acidosis-induced pain [86]. Whilst the roles of individual ASIC isoforms
in nociception have been extensively studied using ASIC knockout mice, the function of homo-
and heteromultimeric channel assemblies in pain pathways requires further investigation [85–87].
Recent evidence shows that at least three subunits are required to form a functional ASIC, where
ASIC1a, ASIC1b, ASIC2a and ASIC3 can form homomultimers and heteromultimers with other ASIC
subunits, the exception being that ASIC2b cannot form a homomultimer [87,88].
Many venoms are acidic, and it is thus not surprising that acid-sensitive channels such as ASICs
might contribute to venom-induced pain either through proton-mediated activation or indirectly as a
result of inflammation-induced tissue acidification. However, despite the prominence of ASIC channels
in pain pathways, only one venom component that directly activates ASICs has been described so
far—MitTx, a 20.8 kDa heteromeric toxin complex from the Texas coral snake Micrurus tener tener [89].
MitTx is composed of a Kunitz- and a phospholipase A2-like protein and elicits large, non-inactivating
currents from ASIC1- and ASIC3-containing channels, as well as sensitising ASIC2a homomers to
protons [89]. Indeed, nocifensive licking responses elicited by intraplantar injection of MitTx were
virtually abolished in ASIC1−/− mice, despite the injected concentration being orders of magnitude
greater than the in vitro EC50 at ASIC1-containing channels (9.4–23.0 nM) [89]. While MitTx remains
the only ASIC-activator toxin described to date, it is plausible that similar mechanisms are conserved
across other species.
7. Phospholipase A2
Arachnid, insect, cnidarians, and snake venoms are particularly rich sources of phospholipase
A2 (PLA2), an enzyme that catalyses the hydrolysis of phospholipids to produce arachidonic acid
and lysophosphatidic acid [90,91]. Conversion of arachidonic acid to eicosanoids and leukotrienes
facilitates activation of sensory neurons via inflammatory signalling cascades. The toxicity of secreted
venom phospholipases A2 can vary significantly, involving complex pharmacological activities that
ultimately lead to neurotoxic and/or myotoxic effects. Venom-derived PLA2s can be divided into
structurally and functionally distinct subtypes: the snake-venom derived type 1 and 2 PLA2s; type 3
from Heloderma suspectum, Heloderma horridum horridum and Apis mellifera; and type 4, which consists
of 40–80 amino acid residue peptides that are secreted by some cone snails.
Envenomation with snake venom PLA2s can have a range of biological effects, most notably
neuromuscular toxicity, myotoxicity, cardiotoxicity, haemolytic and anti-coagulant effects, as well
as organ and tissue damage [92]. Extracellular lysophospholipids and fatty acids, particularly
lysophosphatidylcholine, recapitulate several aspects of the neuromuscular effects of envenomation
with PLA2-containing venoms [93]. However, the role of venom-derived PLA2s in pain, as well as their
effects on sensory neurons, is unclear. Mammalian PLA2 is an important contributor to inflammatory
processes, with arachidonic acid derivatives produced downstream of enzyme activity contributing to
sensitisation of sensory neurons, for example via activation of TRPV1 [94]. Accordingly, venom-derived
PLA2s are also known to induce inflammation, and these processes most likely contribute to activation
of nociceptors. However, enzymatically inactive venom-derived PLA2s are still able to elicit pain,
suggesting that PLA2 as an inert molecule may activate nociceptive pathways [92,95,96]. Indeed,
secreted PLA2s can (in addition to causing cytolytic effects and binding to M-type or other PLA2
receptors) directly block neuronal KV channels, thus enhancing the duration of presynaptic membrane
depolarisation [90,97,98]. This activity contributes to neuromuscular effects, and likely—as discussed
above—also enhances excitability of sensory neurons [97]. This pharmacological promiscuity makes it
difficult to unravel the precise contribution of PLA2s to pain resulting from envenomation.
For instance, melittin, a major pain-producing component from the venom of the honey bee
Apis mellifera, is commonly described as a toxin mediating its effects via activation of PLA2. Indeed,
melittin induces hyperactivity of PLA2, possibly as a result of Ca2+ influx [99]. Melittin, however,
is a multifaceted toxin, as it also causes pore formation which may contribute to activation of
nociceptors [100]. In addition, subcutaneous administration of melittin up-regulates voltage gated
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sodium channels NaV1.8 and NaV1.9, key ion channels involved in propagation of action potentials in
sensory neurons [101].
8. Pore-Forming Venom Peptides
Pore-forming peptides are typically produced by bacteria, but are also found in many types of
venoms, including cnidarians, ants, spiders, bees and wasps. These toxins are frequently cytolytic due
to their ability to disrupt cellular membranes [102]. These peptides principally function based on their
charge distribution as well as the phospholipid composition of cellular membranes [102]. Binding to
target membranes can involve specific receptors such as cholesterol, sphingomyelin or membrane
proteins, making some pore-forming toxins cell-type specific [103]. The proposed mechanism of
pore formation involves a time-dependent build-up of the peptide in the lipid bilayer in a toroidal
or barrel stave fashion which forms the pore [104]. In the toroidal mechanism, the pore-forming
peptide accumulates and covers the surface of the outer phospholipid bilayer [102]. Subsequently,
the peptides are integrated into the outer bilayer and expansion occurs in a manner that leaves the
inner phospholipid bilayer smaller than the outer, with a toroidal pore forming by the bending of the
inner bilayer [102]. Barrel stave peptides function in the same manner except they do not bend the
inner bilayer [102]. The resultant transmembrane pores compromise membrane integrity and permit
passage of ions and signalling molecules, leading to diverse biological effects.
Direct nociceptive effects have been shown for δ-myrtoxin-Mp1a, an α-helical peptide from the
venom of the Jack Jumper ant Myrmecia pilosula [105]. Activity of Mp1a was initially assessed using
dual-polarization interferometry, which showed disruption of phospholipid bilayers due to irreversible
binding. This activity in turn results in a concentration-dependent transient increase in intracellular
Ca2+ ions in vitro. Accordingly, local intraplantar injection of the toxin causes spontaneous pain as
well as mechanical allodynia [105].
A similar mechanism also contributes to the pain-inducing effects of α-haemolysin, a pore forming
toxin produced by Staphylococcus aureus [106]. α-Haemolysin is secreted by Staphylococcus aureus and
is a known pore-forming toxin responsible for tissue damage, inflammation and bacterial migration.
Insertion of α-haemolysin into cell membranes leads to formation of heptameric pores that allow cation
influx, including in sensory neurons [106]. As a result, neuronal depolarisation leads to spontaneous
action potential firing, an effect that is absent with a mutant α-haemolysin protein that does not form a
stable pore [106]. In principle, any pore-forming toxin that is able to target the membranes of sensory
neurons is likely to affect excitability of nociceptors and may thus lead to pain. In addition, cytolytic
effects of these toxins could lead to lysis of non-neuronal cells in the skin and subsequent inflammatory
activation of nociceptors. However, the contribution of these mechanisms to venom-induced pain has
not been assessed systematically.
9. Conclusions
Studies focusing on the venoms produced by a myriad of species have provided crucial insight
into prey–predator interactions. By isolating the thousands of different peptide components of
these venoms, the field has provided new insights into venom-targeted channels and receptors.
By taking advantage of millions of years of evolution, researchers have gained highly valuable
insights into sensory function and pain signalling in physiological and pathological conditions. Finally,
these venom-derived compounds have allowed elucidation of ion channel gating and activation
mechanisms, and even species evolution of ion channels and their function.
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